Drug reps will promote Avandia (rosiglitazone) as more effective than metformin for initial therapy of type 2 diabetes
Drug reps will promote Avandia (rosiglitazone) as more effective than metformin for initial therapy of type 2 diabetes.
They're citing a new study that suggests patients maintain control longer with rosiglitazone than with metformin or glyburide.
You'll hear that 5-year treatment failures are 32% higher with metformin and 63% higher with glyburide compared to rosiglitazone.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote